Key points are not available for this paper at this time.
Abstract The yeast Cryptococcus neoformans is an opportunistic human pathogen capable of surviving within various environmental conditions. The repertoire of antifungal agents effective in treating cryptococcal infection is limited, necessitating the identification of alternative treatment strategies. Nonsense-mediated decay (NMD) is an RNA decay mechanism that serves as a post-transcriptional regulator of gene expression. While the absence of NMD in C. neoformans sensitizes cells to the antifungal fluconazole, the mechanism underlying this sensitivity and role of NMD in C. neoformans biology remained unexplored. Using phenotypic analysis and RNA-sequencing analysis, we identify basal dysregulation of thermal- and nutrient-adaptive genes and demonstrate temperature- and/or nutrient-dependent phenotypic suppression of upf1 Δ phenotypes, including fluconazole sensitivity and resistance to rapamycin. We determine rapamycin co-treatment also suppresses the upf1 Δ fluconazole sensitivity, implicating dysregulation of Tor signaling in phenotypic outcomes when NMD is absent. We then investigate Tor-sensitive signaling in the upf1 Δ mutant, finding inhibition of cell wall integrity (CWI) signaling and hyperactivation of the kinase Gcn2, both of which returned to wildtype-like levels by either rapamycin treatment, nutrient limitation, or constitutive thermal stress. These results indicated NMD is required for appropriate regulation of Tor signaling in unstressed conditions and suggested upf1 Δ phenotypes are driven in part by Tor hyperactivation. A phenotypic screen of mutants lacking Tor regulators revealed that deletion of the Tor-suppressing IML1 gene recapitulates upf1 Δ phenotypes and signaling defects, consistent with Tor hyperactivation. Taken together, our results suggest NMD participates in the regulation of Tor signaling in C. neoformans . Future work will investigate how specific targets of NMD impact Tor signaling and promote fluconazole sensitivity in C. neoformans . Importance Pulmonary and central nervous system infections cause by Cryptococcus neoformans are responsible for about 112,000 deaths annually. Ten-week mortality remains high at 25% with use of frontline antifungals which imposes major health risks due to inherent toxicity. Thus, a need arises to identify novel avenues of treatment, including ways of boosting the efficacy of widely available antifungals such as fluconazole against C. neoformans. The design of NMD inhibitors is an active pharmaceutical pipeline for use in treating human genetic diseases. Even though NMD is conserved across eukaryotes, underlying components and regulatory roles of NMD differ between humans and fungi. Therefore, understanding NMD within C. neoformans will inform the design and repurposing of NMD inhibitors to enhance the antifungal activity of fluconazole as a treatment for Cryptococcosis.
Duffy et al. (Fri,) studied this question.